The current understanding on the impact of KRAS on colorectal cancer

Mingjing Meng, Keying Zhong, Ting Jiang, Zhongqiu Liu*, Hiu Yee Kwan*, Tao Su*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.
Original languageEnglish
Article number111717
Number of pages13
JournalBiomedicine and Pharmacotherapy
Volume140
DOIs
Publication statusPublished - Aug 2021

User-Defined Keywords

  • Colorectal cancer
  • KRAS
  • Mutation
  • Therapy

Fingerprint

Dive into the research topics of 'The current understanding on the impact of KRAS on colorectal cancer'. Together they form a unique fingerprint.

Cite this